SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense market volatility and polarizing sentiment as traders debate whether it is a legitimate high-growth asset or a manipulated pump-and-dump scheme. The community is actively tracking major upcoming music events and supply concentration concerns while comparing the token's explosive price action to similar high-beta opportunities.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is trending as investors show strong interest in its potential for a mid-term rally, with many in the community highlighting its undervalued status relative to its TVL and its role as a benchmark DeFi lending protocol. The discourse is fueled by bullish technical setups, speculation around institutional integration, and debates comparing its tokenomics and governance to other major lending platforms.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is gaining momentum among retail traders who view the low-cap project as a high-potential, long-term opportunity within the rapidly expanding AI crypto sector. Community members are actively comparing the token's growth prospects against established AI infrastructure assets, emphasizing its status as an emerging, under-the-radar play.

Murphy Oil Corp. is a holding company, which engages in the exploration and production of oil and natural gas. It operates through the Exploration and Production, and Corporate and Other segments. The Exploration and Production segment includes the United States, Canada, and all other countries. The Corporate and Other segment focuses on interest income, other gains and losses, interest expense, and unallocated overhead. The company was founded by Charles H. Murphy Jr. in 1950 and is headquartered in Houston, TX.

Murphy Oil Corp.

Murphy Oil is drawing significant investor interest as analysts highlight its strong production growth and strategic focus on key offshore assets in the Gulf of Mexico and Vietnam. The community is actively debating the company's long-term potential, with a mix of optimism surrounding its recent earnings performance and ongoing discussions about debt management and global economic pressures in the energy sector.

Qnity Electronics, Inc. engages in the manufacturing of electronic materials to the semiconductor and electronics industries. Its brands include Acuplane, Circuposit, Duroptix, EPIC, Ikonic, Kalrez, Kapton, Laird, Microfill, Pyralux, Riston, Solderon Tin, and Silveron Silver. Its products include printed circuit board materials, display materials, electrical insulation materials, electronic components, semiconductor fabrication and packaging materials, thermal management materials, general metal finishing, plating on plastics, silver nanowire technologies, and other related products. It operates through the Semiconductor Technologies and Interconnect Solutions segments. The Semiconductor Technologies segment provides a portfolio of innovative materials and solutions utilized across multiple stages of the semiconductor manufacturing process. The Interconnect Solutions segment offers solutions for advanced electronics hardware, including complex printed circuit boards and advanced semiconductor packaging. The company was founded on December 6, 2024 and is headquartered in Wilmington, DE.

Qnity Electronics Inc

Qnity Electronics is attracting significant attention as traders identify it as a key beneficiary of the semiconductor and data center supply chain, compounded by its inclusion in Apple's American Manufacturing Program. The community is heavily focused on its post-spinoff structure and technical breakout potential, with many discussing its long-term growth prospects as a 'hidden gem' and potential multi-year compounder.

Tidal Trust II - Defiance Daily Target 2X Long IREN ETF

Defiance Daily Target 2X Long IREN ETF

The Defiance Daily Target 2X Long IREN ETF ($IRE) is seeing heavy social media volume as traders speculate on the aggressive price action of its underlying asset, with community members actively discussing the potential for a rebound following recent volatility. While some participants are aggressively "loading the boat" on dips and highlighting the strength of the data center sector, others are exercising caution with stop-losses and hedging strategies amid broader market uncertainty.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy is trending as investors focus on its progress within the Department of Energy's pilot program and potential advancements in molten salt reactor technology. While some community members highlight upcoming regulatory milestones and strong cash reserves, others express skepticism regarding the company's long-term commercial timeline and the absence of concrete revenue, leading to active debate over its valuation.

Daddy Darth Sidious

SIDIOUS is gaining traction alongside DARTH as part of a competitive, themed 'daddy wars' community narrative. Participants are actively debating potential market rotations and speculative entry points while emphasizing long-term holding strategies for these nano-cap assets.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to significant speculation surrounding the potential appointment of a former company executive as the new director of the FDA's Center for Biologics Evaluation and Research (CBER). The community is actively discussing this news as a major catalyst for the accelerated approval of Deramiocel, with many viewing the company's strong clinical data and exosome technology as a golden opportunity.

Daddy Darth Vader

The community is actively engaged in a rivalry known as the Daddy Wars, pitting DARTH against other related meme coins in a battle for market dominance. Traders are debating the project's long-term potential and the transparency of its leadership while weighing the risks of low-market-cap assets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Galapagos NV (NASDAQ:GLPG) Expands By 20.4%

Galapagos NV (NASDAQ:GLPG - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,096,114 shares, an increase of 20.4% from the March 15th total of 910,692 shares. Currently, 1.7% of the company's...

Galapagos (NASDAQ:GLPG) Stock Crosses Below 200 Day Moving Average - Time to Sell?

Galapagos (NASDAQ:GLPG) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell...

Galapagos NV (NASDAQ:GLPG) Given Average Recommendation of "Hold" by Analysts

Galapagos NV (NASDAQ:GLPG - Get Free Report) has been assigned an average recommendation of "Hold" from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One...

Galapagos Partners With Gilead on Gamgertamig, Unlocks $500M Cash and Eyes 2027 Registrational Trials

Galapagos (NASDAQ:GLPG) said it has entered into a binding collaboration agreement with Gilead focused on Gamgertamig, a BCMA x CD3 T-cell engager being developed for autoimmune diseases. Chief Executive Officer Henry Gosebruch said the deal follows "advanced discussions" disclosed the prior week an...

Galapagos (NASDAQ:GLPG) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Galapagos from a "hold" rating to a "buy" rating in a research note on Saturday...

Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal

GILD expands into autoimmune therapies with an acquisition deal with Ouro Medicines, adding OM336 and advancing its push into next-gen immunology platforms.

Galapagos (NASDAQ:GLPG) Sees Large Volume Increase - Still a Buy?

Galapagos (NASDAQ:GLPG) Sees Large Volume Increase - Should You Buy...

Galapagos Q4 Earnings Call Highlights

Galapagos (NASDAQ:GLPG) executives used the company's year-end 2025 financial results call to outline a strategic reset centered on business development, following a decision to wind down its cell...

Galapagos (NASDAQ:GLPG) Shares Gap Up Following Earnings Beat

Galapagos (NASDAQ:GLPG) Shares Gap Up Following Better-Than-Expected Earnings...

<ul class="summary-bullets"><li>The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company said.&nbsp;</li><li>It will also result in the shut down of sites in the Netherlands, Switzerland, U.S. and China.</li><li>Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.</li></ul> Galapagos NV (GLPG) on Monday announced that its Board of Directors has decided to initiate the wind-down of the company’s cell therapy activities, sending shares up 6% in Monday’s after hours trading.The company had announced its intent to wind down the activities after a strategic review and sale process in October but had held on acting on it until it completed communicating with work councils in the Belgium and Netherlands. The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/05/3213177/0/en/Galapagos-Announces-Board-Decision-to-Initiate-Wind-Down-of-Cell-Therapy-Activities.html">said</a>.It will also result in the shut down of sites in the Netherlands, Switzerland, the U.S. and China. The U.S. facilities to be shut down include one in Princeton and another in Pittsburgh, the company said. More details about the wind down, including details pertaining to its timeline and costs, will be provided with the company’s full year earnings in February, it added.Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.<h2 class="st-heading-2">Future After Wind Down</h2>On Monday, Galapagos said that the wind-down of the cell therapy activities will position it for longer-term growth. The company will continue to manage its non-cell therapy programs and evaluate all strategic alternatives for GLPG3667, an investigational, oral, selective inhibitor of tyrosine kinase 2, to accelerate its development in dermatomyositis and potentially other severe auto-immune indications, the company said.The company will also consider resuming the partnering process for the drug, it said. Galapagos also added that it will continue to maintain its presence at its headquarters in Belgium as well as its hubs in Chicago and San Francisco.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment about GLPG stayed in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<a href="https://stocktwits.com/symbol/GLPG">GLPG stock</a> has gained 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/toyota-us-sales-rise-8-percent-in-q4/cmxMCZPR4Ri">US Heeds Trump To Buy A Toyota: Japanese Automaker’s US Sales Rise 8% In Q4</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A logo of Galapagos, a European pharmaceutical research company, is pictured outside its facility on June 9, 2020 in Leiden, Netherlands. (Photo by Yuriko Nakao/Getty Images) 

Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Subsequent Workforce Reduction 

The company had announced its intent to wind down the activities after a strategic review and sale process in October.

Equity

The company had announced its intent to wind down the activities after a strategic review and sale process in October.


Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

GLPG
Galapagos

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GLPG News

GLPGGalapagos